Lerner Research Institute News
Read about the latest advances from Lerner Research Institute scientists, including new findings, grant awards, innovations and collaborations.
Investigating the Biology of Sex-Based Differences in COVID-19
Dr. Sharifi and a team of respiratory and prostate cancer researchers studied how a male sex hormone involved in prostate cancer may provide clues to why men are more likely to develop COVID-19 and have poorer disease-related outcomes than women.
Researchers at Cleveland Clinic are in search of the biological reason behind why men are more likely than women to develop COVID-19 and typically have more severe disease.
According to new study results published in Scientific Reports, levels of the protein ACE2 (angiotensin converting enzyme 2) are modestly higher in human males versus females and preclinical models. ACE2, along with the protein TMPRSS2 (transmembrane serine protease 2), are the main human entry points for SARS-CoV-2, the virus that causes COVID-19, leading researchers to wonder if sex-based differences in expression levels may offer insights into why men have worse COVID-19-related disease and outcomes than women.
Taking clues from prostate cancer research
TMPRSS2 (the gene that encodes the TMPRSS2 protein) has been linked to prostate cancer. Male sex hormones called androgens regulate TMPRSS2 gene expression and are involved in the growth and spread of prostate cancer.
“Since androgens are much higher in males, the general question was whether androgens might explain sex-related differences in COVID-19,” explained Nima Sharifi, MD, director of the Cleveland Clinic Genitourinary Malignancies Research Center and lead author on the study. “Although prostate cancer research shows that androgen receptors regulate TMPRSS2 in the prostate, we do not yet understand sex-based differences in androgen receptor expression in the lungs, or any of the receptor’s downstream targets in respiratory tissues.”
A closer look at protein expression in the lungs
In this study, Dr. Sharifi’s team compared ACE2 and TMPRSS2 expression in the lung tissue of male versus female patients, and male versus female mouse models. While the researchers found no difference in male versus female expression of TMPRSS2, male preclinical models and male patients who smoked expressed higher levels of ACE2 in the lungs than their female counterparts.
They treated the mice with an anti-androgen drug called enzalutamide to determine if ACE2 or TMPRSS2 levels changed as a result. TMPRSS2 levels didn’t change, but blocking androgen receptors did result in modestly reduced ACE2 expression.
“Based on our findings, we observed two things. First, it appears that ACE2 expression in the lungs may be at least partially regulated by androgens, which could have implications for SARS-CoV-2 infection, although these are rather modest changes,” said Dr. Sharifi. “We also learned that levels of ACE2—the primary human entry point for the virus—are different between male and female smokers.”
More research will be necessary to determine if this sex-based variance in ACE2 levels is observed among COVID-19 patients, and will be tested in several ongoing clinical trials.
Mehdi Baratchian, PhD, a postdoctoral fellow in Dr. Sharifi’s lab, was first author on the study, which was supported by the National Cancer Institute and Prostate Cancer Foundation.